

PricePlow Mike

Patient Information Specimen Information **Client Information PricePlow Mike** Lab Ref #: **REQUEST A TEST - PWN HEALTH** AGE: 37 Gender: M Fasting: Y 07/05/2019 Collected: Received: 07/07/2019 / 13:08 CDT Reported: 07/11/2019 / 12:58 CDT FASTING:YES **COMMENTS:** In Range Out Of Range Reference Range Test Name Lab LIPID PANEL, STANDARD CHOLESTEROL, TOTAL 193 <200 mg/dLIG HDL CHOLESTEROL >40 mg/dL 56 TG TRIGLYCERIDES 41 <150 mg/dL IG LDL-CHOLESTEROL 125 H mg/dL (calc) IG Reference range: <100 Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors. LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO <5.0 (calc) 3.4 IG NON HDL CHOLESTEROL 137 H <130 mg/dL (calc) IG For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP IG 0 9 mq/L Reference Range Optimal <1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87. For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines Lower relative cardiovascular risk. <1.0 1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk. Consider retesting in 1 to 2 weeks to exclude a benign transient elevation in the baseline CRP value secondary to infection or inflammation. Persistent elevation, upon retesting, >10.0 may be associated with infection and inflammation. COMPREHENSIVE METABOLIC IG PANEL GLUCOSE 65-99 mg/dL 88 Fasting reference interval 7-25 mg/dL UREA NITROGEN (BUN) 20 CREATININE 1.05 0.60-1.35 mg/dL eGFR NON-AFR. AMERICAN 90 > OR = 60 mL/min/1.73m2eGFR AFRICAN AMERICAN 105 > OR = 60 mL/min/1.73m26-22 (calc) BUN/CREATININE RATIO NOT APPLICABLE

CLIENT SERVICES: 866.697.8378

and the second states of the second sec

Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics.

.



Patient Information	Specimen Information		
	Specimen:	and the Automatic	
	• 3135	and the second se	
	Collected: 07/05/2019	a set Descent in the set	
AGE: 37	Received: 07/07/2019 / 13:08 CDT		
Gender: M Fasting: Y	Reported: 07/11/2019 / 12:58 CDT		
Patient ID:			
lealth ID:			
	To Dana and Of Dana	Defense Deser	T - 1-
Test Name	In Range Out Of Range	Reference Range	Lab
SODIUM	140	135-146 mmol/L	
POTASSIUM	4.8	3.5-5.3 mmol/L	
CHLORIDE	105	98-110 mmol/L	
CARBON DIOXIDE	26	20-32 mmol/L	
CALCIUM	9.1	8.6-10.3 mg/dL	
PROTEIN, TOTAL	6.9	6.1-8.1 g/dL	
ALBUMIN	4.2	3.6-5.1 g/dL	
GLOBULIN	2.7	1.9-3.7 g/dL (calc)	
ALBUMIN/GLOBULIN RATIO	1.6	1.0-2.5 (calc)	
BILIRUBIN, TOTAL	0.7	0.2-1.2 mg/dL	
ALKALINE PHOSPHATASE	53	40-115 U/L	
AST	20	10-40 U/L	
ALT	25	9-46 U/L	
HEMOGLOBIN A1C WITH EAG	20		IG
HEMOGLOBIN AIC WITH EAG	5.2	<5.7 % of total Hgb	10
For the purpose of screen		CJ.7 % OI COCAI IIgD	
diabetes:	ling for the presence of		
diabeles:			
	ith the absence of diabetes		
	ith increased risk for diabetes		
(prediabetes)			
> or =6.5% Consistent w:	ith diabetes		
	sistent with a decreased risk		
of diabetes.			
Currently, no consensus e			
hemoglobin Alc for diagno	osis of diabetes in children.		
According to American Dia			
guidelines, hemoglobin A:	lc <7.0% represents optimal		
control in non-pregnant of	liabetic patients. Different		
	cific patient populations.		
Standards of Medical Care			
eAG (mg/dL)	103	(calc)	
eAG (mmol/L)	5.7	(calc)	
INSULIN	2.2	2.0-19.6 uIU/mL	IG
		2.0 19.0 010/111	10
This inculin accour chouse			
This insulin assay shows			
some insulin analogs (lis	spro, aspart, and glargine)		
some insulin analogs (lis and much lower cross-read			
some insulin analogs (lis and much lower cross-read glulisine).	spro, aspart, and glargine)		
some insulin analogs (lis and much lower cross-read glulisine). TESTOSTERONE, TOTAL,	spro, aspart, and glargine) ctivity with others (detemir,		IG
some insulin analogs (lis and much lower cross-read glulisine). TESTOSTERONE, TOTAL, MALES (ADULT), IA	spro, aspart, and glargine) ctivity with others (detemir, 791	250-827 ng/dL	
some insulin analogs (lis and much lower cross-read glulisine). TESTOSTERONE, TOTAL,	spro, aspart, and glargine) ctivity with others (detemir,	250-827 ng/dL 46.0-224.0 pg/mL	
some insulin analogs (lis and much lower cross-read glulisine). TESTOSTERONE, TOTAL, MALES (ADULT), IA TESTOSTERONE, FREE	spro, aspart, and glargine) ctivity with others (detemir, 791 66.1	5.	
some insulin analogs (lis and much lower cross-read glulisine). TESTOSTERONE, TOTAL, MALES (ADULT), IA TESTOSTERONE, FREE This test was developed	spro, aspart, and glargine) ctivity with others (detemir, 791 66.1 and its analytical performance	46.0-224.0 pg/mL	
some insulin analogs (lis and much lower cross-read glulisine). TESTOSTERONE, TOTAL, MALES (ADULT), IA TESTOSTERONE, FREE This test was developed characteristics have been	spro, aspart, and glargine) ctivity with others (detemir, 791 66.1 and its analytical performance determined by Quest Diagnostic	46.0-224.0 pg/mL cs Nichols	
some insulin analogs (lis and much lower cross-read glulisine). TESTOSTERONE, TOTAL, MALES (ADULT), IA TESTOSTERONE, FREE This test was developed characteristics have been Institute Valencia. It ha	spro, aspart, and glargine) ctivity with others (detemir, 791 66.1 and its analytical performance determined by Quest Diagnostic as not been cleared or approved	46.0-224.0 pg/mL cs Nichols by the US	
some insulin analogs (lis and much lower cross-read glulisine). TESTOSTERONE, TOTAL, MALES (ADULT), IA TESTOSTERONE, FREE This test was developed characteristics have been Institute Valencia. It ha	spro, aspart, and glargine) ctivity with others (detemir, 791 66.1 and its analytical performance determined by Quest Diagnostic	46.0-224.0 pg/mL cs Nichols by the US	
some insulin analogs (lis and much lower cross-read glulisine). TESTOSTERONE, TOTAL, MALES (ADULT), IA TESTOSTERONE, FREE This test was developed characteristics have been Institute Valencia. It has Food and Drug Administrat	spro, aspart, and glargine) ctivity with others (detemir, 791 66.1 and its analytical performance determined by Quest Diagnostic as not been cleared or approved tion. This assay has been valida	46.0-224.0 pg/mL cs Nichols by the US ated	
some insulin analogs (lis and much lower cross-read glulisine). TESTOSTERONE, TOTAL, MALES (ADULT), IA TESTOSTERONE, FREE This test was developed characteristics have been Institute Valencia. It has Food and Drug Administrat pursuant to the CLIA regu	spro, aspart, and glargine) ctivity with others (detemir, 791 66.1 and its analytical performance determined by Quest Diagnostic as not been cleared or approved	46.0-224.0 pg/mL cs Nichols by the US ated	
some insulin analogs (lis and much lower cross-read glulisine). TESTOSTERONE, TOTAL, MALES (ADULT), IA TESTOSTERONE, FREE This test was developed characteristics have been Institute Valencia. It ha Food and Drug Administrat	spro, aspart, and glargine) ctivity with others (detemir, 791 66.1 and its analytical performance determined by Quest Diagnostic as not been cleared or approved tion. This assay has been valida	46.0-224.0 pg/mL cs Nichols by the US ated	IG SLI
some insulin analogs (lis and much lower cross-read glulisine). TESTOSTERONE, TOTAL, MALES (ADULT), IA TESTOSTERONE, FREE This test was developed characteristics have been Institute Valencia. It has Food and Drug Administrat pursuant to the CLIA regu	spro, aspart, and glargine) ctivity with others (detemir, 791 66.1 and its analytical performance determined by Quest Diagnostic as not been cleared or approved tion. This assay has been valida	46.0-224.0 pg/mL cs Nichols by the US ated	

See 1945 - 1988 - 1988 - 1988 - 1988